胰高血糖素样肽1受体激动剂相关非动脉炎性前部缺血性视神经病变的杯盘比
本研究为回顾性多中心病例对照研究,比较使用司美格鲁肽、非司美格鲁肽GLP-1 RA及未使用GLP-1 RA的NAION患者未受累对侧眼的杯盘比(CDR)。结果显示三组CDR无显著差异,CDR≤0.20者对侧眼NAION风险显著增高(OR=46.3),提示GLP-1 RA暴露不改变NAION患者的拥挤视盘特征。
要点
- NAION患者无论是否暴露于GLP-1 RA,对侧眼CDR均无显著差异。
- 照片测量CDR≤0.20的对侧眼发生NAION的比值比为46.3。
- CDR与NAION风险呈负相关,CDR越小风险越高。
核心结论
- 使用与未使用GLP-1 RA的NAION患者具有相同的高拥挤视盘患病率。
- NAION的比值比与CDR呈负相关,CDR≤0.20时比值比最高。
- 无论是否暴露于GLP-1 RA,照片测量CDR≤0.20的眼发生NAION的比值比是CDR>0.40者的46倍。
研究设计与样本
- 回顾性、多中心、病例对照研究,纳入2018至2024年诊断的NAION病例。
- Disc-at-Risk研究组包含16个神经眼科中心,回顾了2169例连续NAION患者中1812只未受累对侧眼的病历。
- 对照组包括465例患者的双眼。
主要发现
- NAION患者未受累对侧眼的提供者估计平均CDR为0.13,三组间无显著差异。
- 照片测量CDR≤0.40见于94%的对侧眼,而对照组仅56%(P < 0.001)。
- 照片测量CDR≤0.20见于54%的对侧眼照片,而对照组仅9%(P < 0.001)。
- 照片测量CDR≤0.20的眼NAION比值比为46.3(95%置信区间22.9-93.4)。
- 照片测量CDR>0.20且≤0.40的眼NAION比值比为6.8(95%置信区间3.5-13.2),参照组为CDR>0.40的眼。
关键数值与推荐
- 照片测量CDR≤0.20者NAION比值比为46.3(95%置信区间22.9-93.4)。
- 照片测量CDR>0.20且≤0.40者NAION比值比为6.8(95%置信区间3.5-13.2)。
- 对侧眼照片测量CDR≤0.40占94%,对照组占56%(P < 0.001)。
- 对侧眼照片测量CDR≤0.20占54%,对照组占9%(P < 0.001)。
临床怎么用
- 对于关注NAION风险的患者,可依据照片测量CDR量化风险,CDR≤0.20者风险显著增高。
- GLP-1 RA暴露不改变NAION患者对侧眼的拥挤视盘特征,不应仅据此调整用药。
- 本研究未评估GLP-1 RA是否为NAION的独立危险因素,临床决策需综合考虑。
局限性
- 本研究为回顾性设计,可能存在选择偏倚。
- 本研究未评估GLP-1 RA药物是否为NAION的独立危险因素。
- CDR测量依赖提供者估计和照片测量,可能存在测量偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To determine whether the cup-to-disc ratio (CDR) of patients with glucagon-like peptide 1 receptor agonist (GLP-1 RA) -associated nonarteritic anterior ischemic optic neuropathy (NAION) is similar to the CDR of patients with NAION without GLP-1 RA exposure and to stratify the odds of developing NAION based on CDR. DESIGN: A retrospective, multicenter, case-control study of the CDR of NAION cases diagnosed between 2018 and 2024. SUBJECTS AND CONTROLS: The Disc-at-Risk Study Group included 16 neuro-ophthalmology centers that reviewed medical records of 1812 unaffected fellow eyes from 2169 consecutive patients with NAION. The control group included both eyes of 465 patients. METHODS: The study compared the unaffected fellow eyes of 3 groups of patients with NAION: semaglutide users (117 eyes), nonsemaglutide GLP-1 RA users (83 eyes), and No GLP-1 RA medications (1612 eyes). Control eyes defined the distribution of CDR in the general population. MAIN OUTCOME MEASURES: The CDR of unaffected fellow eyes of patients with NAION with and without exposure to GLP-1 RA medications. RESULTS: The average provider-estimated CDR in unaffected fellow eyes of patients with NAION was 0.13, with no significant difference among the 3 groups. A measured CDR ≤ 0.40 was found in 94% of fellow eyes but only 56% of controls (P < 0.001). A measured CDR ≤ 0.20 was found in 54% of fellow eye photographs but only 9% of controls (P < 0.001). Eyes with a measured CDR ≤ 0.20 have the highest NAION odds (odds ratio = 46.3; 95% confidence interval, 22.9-93.4), and eyes with a CDR > 0.20 and ≤0.40 had more modest odds (odds ratio = 6.8; 95% confidence interval, 3.5-13.2) compared with eyes with a measured CDR > 0.40. CONCLUSIONS: Patients with NAION with and without exposure to GLP-1 RA medications have the same high prevalence of crowded optic discs. The odds of NAION are inversely proportional to CDR. Irrespective of GLP-1 RA exposure, eyes with a photo-measured CDR ≤ 0.20 have 46 times greater odds of NAION than eyes with a CDR > 0.40. Although the absolute risk of NAION is low, this quantification of NAION risk may help better inform patients concerned about NAION risk. This study does not assess whether GLP-1 RA medications are an independent risk factor for NAION. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
引用
- Robertson CM, Fung DS, Smith KH, et al. Cup-To-Disc Ratio in Glucagon-Like Peptide 1 Receptor Agonist-Associated Nonarteritic Anterior Ischemic Optic Neuropathy. Ophthalmology. 2026. PMID: 42556433. doi:10.1016/j.ophtha.2026.07.036
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。